OncoMatch/Clinical Trials/NCT07089992
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Is NCT07089992 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Pembrolizumab for sarcoma.
Treatment: Pembrolizumab — The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma. The researchers will also study how the immune system responds to the study treatment. Pembrolizumab is a type of drug called a PD-1 inhibitor. It is designed to block a protein called programmed cell death protein 1 (PD-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Sarcoma
Disease stage
Metastatic disease required
recurrent or metastatic disease not judged to be curable with other means; Measurable disease as per RECIST 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic anti-cancer therapy
Patients must have progressed (in the opinion of the treating investigator) following the most recent line of therapy or stop prior therapy due to toxicity or patient choice.
Cannot have received: anti-PD-1 therapy
No prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
Cannot have received: anti-PD-L1 therapy
No prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
Cannot have received: anti-PD-L2 therapy
No prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
Cannot have received: checkpoint inhibitor
No prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
Cannot have received: allogenic tissue/solid organ transplant
No prior allogenic tissue/solid organ transplant.
Lab requirements
Blood counts
ANC ≥ 1,000 cells/mm^3; Platelets ≥ 100,000 cells/mm^3; Hemoglobin ≥ 9 g/dl
Kidney function
Liver function
Total bilirubin ≤ 1.5 x institutional ULN (patients with known Gilbert disease who have bilirubin level ≤ 3 x ULN may be enrolled); AST and ALT ≤3 x institutional ULN
Cardiac function
Adequate cardiac function, defined as: class II or better New York Heart Association (NYHA) Functional Classification.
Required organ function (specimens to be collected within 14 days of the start of the study intervention)...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) · Uniondale, New York
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07089992 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, anti-PD-L1 therapy, anti-PD-L2 therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages